{
    "name": "fremanezumab",
    "comment": "Rx",
    "other_names": [
        "Ajovy",
        "fremanezumab-vfrm"
    ],
    "classes": [
        "CGRP Monoclonal Antibodies"
    ],
    "source": "https://reference.medscape.com/drug/ajovy-fremanezumab-1000227",
    "pregnancy": {
        "common": [
            "There is pregnancy exposure registry that monitors pregnancy outcomes in women exposed to drug during pregnancy; healthcare providers are encouraged to register pregnant patients, or pregnant women may enroll themselves in registry by calling 1-833-927-2605 or visiting ",
            "There are no adequate data on developmental risk associated with therapy in pregnant women; drug has a long half-life, which should be taken into consideration for women who are pregnant or plan to become pregnant while receiving therapy"
        ],
        "specific": [
            {
                "type": "Clinical considerations",
                "description": [
                    "Published data have suggested that women with migraine may be at increased risk of preeclampsia and gestational hypertension during pregnancy"
                ]
            },
            {
                "type": "Animal data",
                "description": [
                    "Administration to rats and rabbits during the period of organogenesis or to rats throughout pregnancy and lactation at doses resulting in plasma levels greater than those expected clinically did not result in adverse effects on development"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on presence in human milk, effects on breastfed infant, or on milk production",
            "Consider developmental and health benefits of breastfeeding along with the motherâ€™s clinical need for the drug, and any potential adverse effects on breastfed infant from the drug or from the underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "History of serious hypersensitivity reactions to drug or excipients"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Use caution in patients with cardiovascular disease; not studied",
                " "
            ],
            "specific": [
                {
                    "type": "Hypersensitivity reactions ",
                    "description": [
                        "Cases of anaphylaxis, angioedema, rash, pruritus, drug hypersensitivity, urticaria reported within hours to 1 month following administration in clinical trials",
                        "Some reactions led to discontinuation or required corticosteroid treatment",
                        "Consider discontinuing therapy, and institute appropriate therapy if hypersensitivity reaction occurs"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Injection site pain",
            "percent": "5"
        },
        {
            "name": "Immune system disorders",
            "percent": null
        },
        {
            "name": "Anaphylactic reactions and angioedema",
            "percent": null
        }
    ]
}